NASDAQ:PSTI - Pluristem Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.33 +0.02 (+1.53 %)
(As of 09/24/2018 03:31 PM ET)
Previous Close$1.30
Today's Range$1.26 - $1.33
52-Week Range$1.14 - $2.12
Volume6,566 shs
Average Volume172,305 shs
Market Capitalization$148.41 million
P/E Ratio-3.94
Dividend YieldN/A
Beta0.37
Pluristem Therapeutics logoPluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PSTI
CUSIPN/A
Phone972-74-710-7259

Debt

Debt-to-Equity RatioN/A
Current Ratio3.75
Quick Ratio3.75

Price-To-Earnings

Trailing P/E Ratio-3.94
Forward P/E Ratio-5.54
P/E GrowthN/A

Sales & Book Value

Annual Sales$50,000.00
Price / Sales3,021.76
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book5.12

Profitability

EPS (Most Recent Fiscal Year)($0.32)
Net Income$-26,120,000.00
Net MarginsN/A
Return on Equity-84.96%
Return on Assets-66.33%

Miscellaneous

Employees180
Outstanding Shares113,600,000
Market Cap$148.41 million

Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.08. View Pluristem Therapeutics' Earnings History.

When is Pluristem Therapeutics' next earnings date?

Pluristem Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, September, 27th 2018. View Earnings Estimates for Pluristem Therapeutics.

What price target have analysts set for PSTI?

5 analysts have issued 1 year price objectives for Pluristem Therapeutics' shares. Their predictions range from $3.00 to $5.00. On average, they expect Pluristem Therapeutics' share price to reach $4.1250 in the next twelve months. This suggests a possible upside of 214.9% from the stock's current price. View Analyst Price Targets for Pluristem Therapeutics.

What is the consensus analysts' recommendation for Pluristem Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pluristem Therapeutics.

What are Wall Street analysts saying about Pluristem Therapeutics stock?

Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
  • 1. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (7/12/2018)
  • 2. Maxim Group analysts commented, "Pluristem announced a joint project with Indiana University to evaluate PLX- R18 cells in Acute Radiation Syndrome (ARS). The study will be supported with $2.5M in grant funding, and data from the first year of the study will be used to further support a BLA filing." (4/23/2018)

Who are some of Pluristem Therapeutics' key competitors?

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the folowing people:
  • Mr. Zami Aberman, Chairman & Co-CEO (Age 64)
  • Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 47)
  • Mr. Erez Egozi, CFO, Treasurer & Sec. (Age 44)
  • Mr. Boaz Leshem, VP Operations & Manufacturing (Age 58)
  • Efrat Kaduri, Head of Investor & PR

Who are Pluristem Therapeutics' major shareholders?

Pluristem Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (1.30%) and Renaissance Technologies LLC (1.14%). View Institutional Ownership Trends for Pluristem Therapeutics.

Which major investors are selling Pluristem Therapeutics stock?

PSTI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Pluristem Therapeutics.

Which major investors are buying Pluristem Therapeutics stock?

PSTI stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC. View Insider Buying and Selling for Pluristem Therapeutics.

How do I buy shares of Pluristem Therapeutics?

Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pluristem Therapeutics' stock price today?

One share of PSTI stock can currently be purchased for approximately $1.31.

How big of a company is Pluristem Therapeutics?

Pluristem Therapeutics has a market capitalization of $148.41 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-26,120,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Pluristem Therapeutics employs 180 workers across the globe.

What is Pluristem Therapeutics' official website?

The official website for Pluristem Therapeutics is http://www.pluristem.com.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-7259 or via email at [email protected]


MarketBeat Community Rating for Pluristem Therapeutics (NASDAQ PSTI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  262 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  435
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe PSTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel